In the Europe, Middle East and Africa region, we have a comprehensive portfolio across glaucoma and dry eye, and have also expanded into the surgical and vision correction arenas.
Glaucoma and dry eye disease portfolios
At Santen, our glaucoma portfolio includes prescription medicines and a medical device to address every step of the disease. We are also growing our portfolio of treatments for dry eye disease (DED or keratoconjunctivitis sicca), which occurs when there’s a problem with the tear film that normally keeps the eyes moist and lubricated, leading to inflammation and damage.
Santen's global development drug pipeline
Santen's network-based drug discovery and global research and development efforts aim to discover and launch novel therapies in eye health.